The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

For information only - not alarm!

Texas_wedge
Texas_wedge CSN Member Posts: 2,798
in Kidney Cancer #1
FDA Puts 16 Drugs on Watch List

http://www.medscape.com/viewarticle/762205

I noticed two of the 16 with some interest but please note the reassurances I'm quoting below. One of the items is gadolinium contrast dyes and a fuller story is given here

http://www.medscape.com/viewarticle/713593

The other is Nexavar (sorafenib) (slight risk of osteonecrosis of the jaw.

The following indicates that one should not over-react:

"April 17, 2012 — The US Food and Drug Administration (FDA) today issued its latest quarterly list of drugs to monitor after having identified potential signs of serious risks or new safety information in the agency's Adverse Event Reporting System (AERS) database during the last 3 months of 2011."

"The appearance of any drug on the AERS watch list, however, does not mean that the FDA has concluded that the drug actually poses the health risk reported through AERS, the FDA cautioned. It means only that the agency will study these drugs to determine whether there is a causal link. If the FDA establishes this link, it then would consider a regulatory response, such as gathering more information to better characterize the risk, revising the drug's label, or requiring a risk evaluation and mitigation strategy.

"Likewise, the FDA said that it is not suggesting that clinicians should stop prescribing any drugs on the watch list, or that patients should stop taking them. It advises patients with questions about watch-list drugs to discuss them with their clinician."
Like Care

Discussion Boards